Following these observations, our group demonstrated that in gestational age (GA)-matched women with suspected or confirmed preeclampsia, PPI use was associated with lower sFlt-1 and ET-1 levels compared with women not using these drugs.7 Since most women (80%) in the former study were using omeprazole,7 we hypothesized that administering this PPI to women with confirmed preeclampsia could actively decrease the levels of circulating sFlt-1. The gene discussed is EDN1; the disease is preeclampsia.